We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 136 for:    PARTNER | Interventional Studies | Breast Cancer
Previous Study | Return to List | Next Study

Platinum and Polyadenosine 5'Diphosphoribose Polymerisation (PARP) Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer (TNBC) and/or Germline BRCA (gBRCA) Positive Breast Cancer (PARTNER)

This study is currently recruiting participants.
Verified May 2017 by Jean Abraham, University of Cambridge
Sponsor:
ClinicalTrials.gov Identifier:
NCT03150576
First Posted: May 12, 2017
Last Update Posted: May 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborators:
AstraZeneca
Cancer Research UK
Information provided by (Responsible Party):
Jean Abraham, University of Cambridge
  Purpose
This neoadjuvant trial for patients with TNBC and/or gBRCA breast cancer, aims to investigate the safety and efficacy (improvement in pathological Complete Response at surgery) of concurrent platinum-based chemotherapy with olaparib an inhibitor of the PARP enzyme (PARPi).

Condition Intervention Phase
Breast Cancer Drug: Olaparib Drug: Paclitaxel and Carboplatin Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomised, Phase II/III, 3 Stage Trial to Evaluate the Safety and Efficacy of the Addition of Olaparib to Platinum-based Neoadjuvant Chemotherapy in Breast Cancer Patients With TNBC and/or gBRCA.

Resource links provided by NLM:


Further study details as provided by Jean Abraham, University of Cambridge:

Primary Outcome Measures:
  • Stage 1 - Number of participants with treatment-related adverse events as assessed by NCI CTCAE v4.03. [ Time Frame: 1 year - when first 25 patients in each research arm who had received at least one dose of Olaparib protocol treatment have completed their protocol treatment. ]
    Primary outcome measure - safety of the addition of olaparib to three weekly carboplatin/weekly paclitaxel chemotherapy.

  • Stage 2 - pCR rate and completion rate of Olaparib treatment as per protocol. [ Time Frame: 15 months - when pathological complete response (pCR) is available for 53 patients in each of two research arms. ]
    Primary outcome measure - pCR in each of the two research arms. At the end of stage 2, one of the research treatments will be dropped using the 'pick the winner' method.

  • Stage 3 - Efficacy analysis based on pCR at surgery. To be assessed by central review of pathology reports. [ Time Frame: 5.5 years - October 2021 approx. ]
    Primary outcome measure - pCR at surgery after neoadjuvant treatment. pCR rates after neoadjuvant chemotherapy +/- olaparib, defined as no residual invasive carcinoma within the breast (Ductal Carcinoma in situ permitted) AND no evidence of metastatic disease within the lymph nodes.


Secondary Outcome Measures:
  • pCR at surgery - assessed by review of histopathology slides [ Time Frame: Up to 2 years after last patient randomised ]
    pCR at surgery assessed by central pathology review of the diagnosis and surgery slides.

  • Relapse-Free Survival (RFS) [ Time Frame: Up to 10 years after last patient is randomised ]
    Relapse Free Survival (RFS), calculated from date of randomisation to date of first relapse or date of death from all causes, whichever occurs first.

  • Breast cancer specific survival (BCSS) [ Time Frame: Up to 10 years after last patient is randomised ]
    Breast cancer specific survival (BCSS), calculated from date of randomisation to date of death from breast cancer.

  • Distant disease-free survival [ Time Frame: Up to 10 years after last patient is randomised ]
    Distant disease-free survival, calculated from date of randomisation to date of the first distant disease relapse or date of death from all causes, whichever occurs first.

  • Local recurrence-free survival [ Time Frame: Up to 10 years after last patient is randomised ]
    Local recurrence-free survival, calculated from date of randomisation to date of the first local recurrence or date of death from all causes, whichever occurs first.

  • Overall survival (OS) [ Time Frame: Up to 10 years after last patient is randomised ]
    Overall survival (OS), calculated from date of randomisation to date of death from all causes.

  • Time to second cancer (TTSC) [ Time Frame: Up to 10 years after last patient is randomised ]
    Time to second cancer (TTSC), calculated from the date of randomisation to the date of diagnosis of second cancer.

  • pCR in breast alone [ Time Frame: Up to 2 years after last patient is randomised ]
    pCR in breast alone

  • Residual Cancer Burden (RCB) [ Time Frame: Up to 10 years after last patient is randomised ]
    Residual Cancer Burden (RCB) I-III will be assessed by central pathology review.

  • Radiological response - as assessed by radiological response criteria as per RECIST v1.1 [ Time Frame: Up to 2 years after last patient is randomised ]
    Radiological response after 4th and final cycles

  • Treatment related toxicities - as assessed by CTCAE v4.03 [ Time Frame: Up to 10 years after last patient is randomised ]
    Treatment related toxicities

  • Quality of Life [ Time Frame: Up to 10 years after last patient is randomised ]
    Quality of Life (sub-study)


Other Outcome Measures:
  • Discovery and validation of prognostic, pharmacogenetic and pharmacogenomic markers that can be correlated with outcomes (pCR and RFS). [ Time Frame: Up to 15 years after last patient is randomised ]
    Discovery and validation of prognostic, pharmacogenetic and pharmacogenomic markers that can be correlated with outcomes (pCR and RFS) in patients randomised to received olaparib compared with those who are not.


Estimated Enrollment: 527
Study Start Date: May 2016
Estimated Study Completion Date: January 2032
Estimated Primary Completion Date: January 2022 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Control
4 cycles of: Paclitaxel 80mg/m2 Day 1, 8 & 15, every 3 weeks, Carboplatin area under the curve (AUC) 5 Day 1, every 3 weeks
Drug: Paclitaxel and Carboplatin
Paclitaxel I.V. 80mg/m2 in 0.9% sodium chloride 500ml or according to local practice, will be given over 60 minutes on days 1, 8 & 15, every 3 weeks for 4 cycles. Carboplatin I.V. AUC5 in 5% dextrose 500ml or according to local practice, over 30-60minutes on day 1 every 3 weeks for 4 cycles.
Other Name: Taxol and Paraplatin
Experimental: Research 1
4 cycles of: Paclitaxel 80mg/m2 on Days 1, 8 & 15 every 3 weeks, Carboplatin AUC 5 Day 1, every 3 weeks, Olaparib oral 150mg twice daily, Day -2 to Day 10 every 3 weeks
Drug: Olaparib
Patients will self-administer Olaparib by mouth. Olaparib tablets should be taken twice daily at the same time each day approximately 12 hours apart.
Other Name: Lynparza
Drug: Paclitaxel and Carboplatin
Paclitaxel I.V. 80mg/m2 in 0.9% sodium chloride 500ml or according to local practice, will be given over 60 minutes on days 1, 8 & 15, every 3 weeks for 4 cycles. Carboplatin I.V. AUC5 in 5% dextrose 500ml or according to local practice, over 30-60minutes on day 1 every 3 weeks for 4 cycles.
Other Name: Taxol and Paraplatin
Experimental: Research 2
4 cycles of: Paclitaxel 80mg/m2 on Days 1, 8 & 15 every 3 weeks, Carboplatin AUC 5 Day 1, every 3 weeks, Olaparib oral 150mg twice daily, Day 3 to Day 14 every 3 weeks
Drug: Olaparib
Patients will self-administer Olaparib by mouth. Olaparib tablets should be taken twice daily at the same time each day approximately 12 hours apart.
Other Name: Lynparza
Drug: Paclitaxel and Carboplatin
Paclitaxel I.V. 80mg/m2 in 0.9% sodium chloride 500ml or according to local practice, will be given over 60 minutes on days 1, 8 & 15, every 3 weeks for 4 cycles. Carboplatin I.V. AUC5 in 5% dextrose 500ml or according to local practice, over 30-60minutes on day 1 every 3 weeks for 4 cycles.
Other Name: Taxol and Paraplatin

Detailed Description:

Randomised, phase II/III 3 stage trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in breast cancer patients with TNBC and/or gBRCA.

Disease under investigation: Breast Cancer

Purpose of clinical trial: To establish if the addition of olaparib to neoadjuvant platinum-based chemotherapy for Triple Negative Breast Cancer (TNBC) and/or germline BRCA (gBRCA) breast cancer is safe and improves efficacy.

Trial Design: Open label, randomised, 3-stage Phase II/III

Sample Size: Minimum of 527 patients (including at least 220 gBRCA patients equally allocated to the control and the selected research arm).

Non Investigational Medicinal Products: Prophylactic granulocyte-colony stimulating factor (G-CSF) to be given as per local practice and 3 cycles of anthracyclines as per local practice.

Treatment period: A minimum of 21 weeks of chemotherapy followed by surgery.

Procedures: Screening & enrolment

Eligible patients with early breast cancer will be registered and consented for screening:

BRCA mutation test Tumour Infiltrating Lymphocytes(TILs) score Cytokeratin 5/6 (CK5/6), Epidermal Growth Factor Receptor (EGFR) +/-, Androgen Receptor (AR) status by Immunohistochemistry (IHC).

Standard assessment prior to chemotherapy Standard staging to exclude metastatic disease. When eligibility is confirmed, patients will be randomised via a web-based central system which will allocate each patient a unique randomisation number associated with one of the treatment arms.

End of Trial: For patients, the end of trial is after the last follow-up visit or contact with the research team planned 10 years after surgery.

Procedures for safety monitoring during trial: Pharmacovigilance will be performed by the PARTNER Trial Office. Also, the Trial Management Group and the Independent Data and Safety Monitoring Committee will regularly review the patient safety data.

Criteria for discontinuation of trial treatment on safety grounds:

Severe toxicity or inter-current illness, requiring cessation in the judgement of patient's clinician.

Patient within 4 weeks has not recovered from toxicity to an extent that allows further treatment.

Patient unable to comply with trial procedures. Disease progression while on trial treatment. Patient becomes pregnant.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   16 Years to 70 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Aged between 16 and 70.
  • Written informed consent, willing and able to comply with the Protocol for the duration of the trial including undergoing treatment and scheduled visits and examinations.
  • Histologically confirmed invasive breast cancer.
  • ER-negative*, and HER2-negative** breast cancer (TNBC). Patients will be eligible with any PR status but PR expression must be scored.

OR

  • Germline BRCA (gBRCA) mutation positive, HER2 negative, and PgR / ER of any status.
  • T1, T2 or T3 tumours.
  • T4 tumour of any size with direct extension to (a) chest wall or (b) skin. OR Inflammatory carcinoma with tumour of any size. OR

Other Locally Advanced Disease:

  • Involvement of ipsilateral large or fixed axillary lymph nodes, or infra or supraclavicular nodes (>10mm diameter or clinical N2 or N3) and primary breast tumour of any diameter.
  • Involvement of ipsilateral large or fixed axillary lymph nodes, or infra or supraclavicular nodes (>10mm diameter, or clinical N2 or N3), without a primary breast tumour identified, the presence of breast cancer in a Lymph Node (LN) must be histopathologically confirmed by LN biopsy.

OR

Multifocal tumour:

- with at least one tumour with a size>10mm.

  • Patients with bilateral disease are eligible to enter the trial provided that both breast disease meets the above criteria.
  • Be fit to receive the trial chemotherapy regimen in the opinion of the responsible clinician:

Adequate bone marrow, hepatic, and renal function. ECOG performance status of 0, or 1.

  • Treatment should be commenced within 6 weeks of the diagnostic biopsy. In uncommon circumstances, where medically acceptable, treatment is permitted to start within a maximum of 9 weeks of the diagnostic biopsy.
  • Availability of the Tumour Infiltrating Lymphocytes score is required.
  • Availability of CK 5/6 and EGFR +/- Androgen Receptor IHC score.
  • Availability of slides and paraffin embedded tissue blocks from pre-chemotherapy core biopsy and from primary surgical resection is required.
  • Women of child-bearing potential (WCBP), defined as not surgically sterilized or not post-menopausal for at least 24 consecutive months if age ≤55 year or 12 months if age >55 years, must have a negative serum or urine pregnancy test within 14 days prior to randomisation.
  • All WCBP and all sexually active male patients as well as their partners must be aware that they should not conceive during the treatment period and therefore should routinely use effective forms of contraception, throughout their participation in the trial and for at least 6 months after the last dose of trial treatment. Please follow the olaparib contraception guidelines.

Exclusion Criteria:

  • T0 tumour in absence of axillary node >10mm.
  • TNBC with a non-basal phenotype which strongly expresses Androgen Receptor.
  • Previous or concomitant chemotherapy or biological agents used for the treatment of cancer in the last 5 years.
  • Malignancy within the last 5 years except: adequately treated non-melanoma skin cancer; curatively treated in situ cancer of the cervix; ductal carcinoma in situ (DCIS); Stage 1, grade 1 endometrial carcinoma; or other solid tumours including lymphomas (without bone marrow involvement) curatively treated with no evidence of disease for ≥5 years.
  • Patients with myelodysplastic syndrome/acute myeloid leukaemia.
  • Evidence of distant metastasis apparent prior to randomisation.
  • Patients with uncontrolled seizures.
  • Pre-existing sensory or motor neuropathy of CTCAE v4.03, grade ≥2.
  • Concomitant use of known potent CYP3A4 inhibitors and inducers. Consider wash-out periods.
  • Pregnant or breast feeding women.
  • Not suitable for neoadjuvant chemotherapy in the opinion of the responsible clinician.
  • Major surgery within 14 days of starting trial treatment and patients must have recovered from any effects of any major surgery.
  • Any evidence of other disease or any concomitant medical or psychiatric problems which in the opinion of the Investigator would prevent completion of treatment or follow-up. For example:

Evidence of severe or uncontrolled cardiac disease Uncontrolled ventricular arrhythmia Recent myocardial infarction (within 12 months) Active infection including Hepatitis B, Hepatitis C and Human Immunodeficiency virus (HIV). Screening for chronic conditions is not required.

  • ECG with mean resting QTc >470 msec on 2 or more time points within a 24 hour period or family history of long QT syndrome.
  • Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the trial medication
  • Known hypersensitivity to olaparib, carboplatin, paclitaxel or their excipients (including cremophor).
  • Whole blood transfusions in the last 120 days prior to blood sampling for BRCA test as it may interfere with the results (packed red blood cells and platelet transfusions are acceptable).
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03150576


Contacts
Contact: Anne-Laure Vallier +44(0) 1223 348086 anne-laure.vallier@addenbrookes.nhs.uk
Contact: Louise A Grybowicz +44 (0)1223 348447 louise.grybowicz@addenbrookes.nhs.uk

Locations
United Kingdom
Cambridge University Hospitals NHS Foundation Trust & the University of Cambridge Recruiting
Cambridge, Cambridgeshire, United Kingdom, CB2 0QQ
Contact: Anne-Laure Vallier    +44(0) 1223 348086    anne-laure.vallier@addenbrookes.nhs.uk   
Contact: Louise Grybowicz    +44(0)1223 348447      
Sponsors and Collaborators
Cambridge University Hospitals NHS Foundation Trust
AstraZeneca
Cancer Research UK
Investigators
Principal Investigator: Jean Abraham The University of Cambridge, Department of Oncology
Principal Investigator: Helena Earl The University of Cambridge, Department of Oncology
  More Information

Responsible Party: Jean Abraham, Dr Jean Abraham, University of Cambridge
ClinicalTrials.gov Identifier: NCT03150576     History of Changes
Other Study ID Numbers: A093777
First Submitted: July 26, 2016
First Posted: May 12, 2017
Last Update Posted: May 12, 2017
Last Verified: May 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Keywords provided by Jean Abraham, University of Cambridge:
Triple negative breast cancer
germline BRCA
platinum and PARP inhibitor
neoadjuvant chemotherapy
olaparib

Additional relevant MeSH terms:
Breast Neoplasms
Triple Negative Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Paclitaxel
Olaparib
Albumin-Bound Paclitaxel
Carboplatin
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Poly(ADP-ribose) Polymerase Inhibitors
Enzyme Inhibitors